Building Resilience and Agility in the Pharma Supply Chain
On demand webinar recording - now available
Fill the details to view the Webinar
Supply disruptions due to Covid-19 and raw material shortages have significantly impacted pharmaceutical organizations. Increasing demands and limitations in logistics and courier services further tested the supply chains. With new challenges and various environmental factors coming into place, pharmaceutical organizations have embarked on adopting digital analytics , new collaborations with government agencies , focus on sustainable supply chain, and changing the organization's internal structure for focused decision making.
In this webinar, we will take a closer look on the API supply chain and real live case studies on how to predict the impact of disruptions and achieve sustainability targets.
What you will learn:
#1 Global supply chain intelligence and how to - predict the impact of disruptions
#2 Integrated business planning
#3 Sustainable supply chains: Reducing the carbon footprint in - the supply chains
#4 Managing Covid-19 induced disruptions and robust business continuity plans
Speakers
Dr. Ravi Prakash Mathur
Vice President and Global Head of Logistics and Supply Chain Excellence Dr. Reddy’s Laboratories Ltd.
Summary of the Webinar
In this webinar, Dr. Ravi Prakash Mathur, Vice President and Global Head of Logistics and Supply Chain Excellence, Dr. Reddy's Laboratories Ltd, addresses - the API supply chain challenges and supply chain management in the pharmaceutical industry complemented with live case studies on how to predict the impact of supply disruptions and achieve sustainability targets.
The first section of the webinar provides insights on sustainability pharmaceutical supply chain focusing on reducing the carbon footprint in the supply chains and logistics and Dr. Reddy's journey in sustainability so far, covering aspects of product responsibility, transparency, operational excellence, and human dignity, equal opportunity, and community development.
The following section covers - managing COVID-19 induced disruptions and business continuity planning and interventions in response to the pandemic and supply chain management in pharmaceutical industry. The role of collaboration in managing disruptions – Strong partner network, cross-industry collaboration groups and opening to new possibilities, leveraging data for LDM & reviewing operations, slicing, and dicing of data for identifying levers for LDM and third-party risk management for sourcing.
The next section of the webinar gives information on digital transformation, integrated business planning (IBP) - project O2: one team, one plan vision, and key objectives, IBP platform features, framework, cross-functional processes, and change management steps. The final session covers – global supply chain intelligence, predicting the impact of disruptions, market intelligence, and critical benefits of procurement dashboards.
Pharmaceutical supply chain management have become complex and become prone to disruptions. As a result, there is a need to keep an eye on and be aware of emerging external scenarios and assess their impact on customer product availability. Supply uncertainty also impacts organizational performance and must synchronize the business processes to create visibility of various performance indicators in advance.
Are you interested in learning more about our global supply chain intelligence, pharmaceutical supply chain, integrated business plan, carbon footprint, managing COVID-19 induced disruptions, and robust business continuity plans? Then contact us at [email protected]
Estamos aquí para ayudarte, si tienes algún requisito específico para tu país.
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.